Gilead Sciences Inc

• Gilead partnered with Vir Biotechnology to develop next-generation oncology therapies. • Strong HIV franchise performance and bullish analyst coverage drove momentum. • The stock closed higher despite intraday volatility and profit-taking.

• Gilead partnered with Vir Biotechnology for solid tumor T-cell engager therapies. • Bank of America raised Gilead price targets on strong HIV therapy outlook. • Gilead reported annual revenue of $29.44B and net profit of $8.51B.

• Gilead pulled back due to profit-taking following a sustained multi-month rally. • Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises. • Analysts maintain Buy ratings with an average price target of $157.79.

• Gilead raised full-year sales guidance driven by accelerated HIV portfolio growth. • A federal court injunction blocked foreign importation to protect core market share. • Analysts issued Buy ratings with an average price target of $157.79.

• A federal court injunction blocks foreign importation of Gilead's key HIV medications. • Robust base-business revenue growth and raised guidance drove positive market sentiment. • Strategic oncology investments and bullish institutional options activity supported equity momentum.

• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.